Your browser doesn't support javascript.
loading
MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model.
Blackman, Alexandra; Rees, Amy C; Bowers, Robert R; Jones, Christian M; Vaena, Silvia G; Clark, Madison A; Carter, Shelby; Villamor, Evan D; Evans, Della; Emanuel, Anthony J; Fullbright, George; O'Malley, Matthew S; Carpenter, Richard L; Long, David T; Spruill, Laura S; Romeo, Martin J; Orr, Brian C; Helke, Kristi L; Delaney, Joe R.
Afiliação
  • Blackman A; Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina.
  • Rees AC; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Bowers RR; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Jones CM; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Vaena SG; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Clark MA; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Carter S; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Villamor ED; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Evans D; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Emanuel AJ; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Fullbright G; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • O'Malley MS; Department of Medical Sciences, Indiana University Bloomington, Bloomington, Indiana.
  • Carpenter RL; Department of Medical Sciences, Indiana University Bloomington, Bloomington, Indiana.
  • Long DT; Department of Biochemistry and Molecular Biology, Indiana University Bloomington, Bloomington, Indiana.
  • Spruill LS; Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
  • Romeo MJ; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Orr BC; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Helke KL; Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina.
  • Delaney JR; Department of Comparative Medicine, Medical University of South Carolina, Charleston, South Carolina.
Cancer Res Commun ; 4(9): 2525-2538, 2024 Sep 01.
Article em En | MEDLINE | ID: mdl-39225558
ABSTRACT
Genetically engineered mouse models (GEMM) have fundamentally changed how ovarian cancer etiology, early detection, and treatment are understood. MYC, an oncogene, is amongst the most amplified genes in high-grade serous ovarian cancer (HGSOC), but it has not previously been utilized to drive HGSOC GEMMs. We coupled Myc and dominant-negative mutant p53-R270H with a fallopian tube epithelium (FTE)-specific promoter Ovgp1 to generate a new GEMM of HGSOC. Female mice developed lethal cancer at an average of 14.5 months. Histopathologic examination of mice revealed HGSOC characteristics, including nuclear p53 and nuclear MYC in clusters of cells within the FTE and ovarian surface epithelium. Unexpectedly, nuclear p53 and MYC clustered cell expression was also identified in the uterine luminal epithelium, possibly from intraepithelial metastasis from the FTE. Extracted tumor cells exhibited strong loss of heterozygosity at the p53 locus, leaving the mutant allele. Copy-number alterations in these cancer cells were prevalent, disrupting a large fraction of genes. Transcriptome profiles most closely matched human HGSOC and serous endometrial cancer. Taken together, these results demonstrate that the Myc and Trp53-R270H transgenes were able to recapitulate many phenotypic hallmarks of HGSOC through the utilization of strictly human-mimetic genetic hallmarks of HGSOC. This new mouse model enables further exploration of ovarian cancer pathogenesis, particularly in the 50% of HGSOC which lack homology-directed repair mutations. Histologic and transcriptomic findings are consistent with the hypothesis that uterine serous cancer may originate from the FTE.

SIGNIFICANCE:

Mouse models using transgenes which generate spontaneous cancers are essential tools to examine the etiology of human diseases. Here, the first Myc-driven spontaneous model is described as a valid HGSOC model. Surprisingly, aspects of uterine serous carcinoma were also observed in this model.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Uterinas / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas c-myc / Cistadenocarcinoma Seroso / Modelos Animais de Doenças Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Commun Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Uterinas / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas c-myc / Cistadenocarcinoma Seroso / Modelos Animais de Doenças Limite: Animals / Female / Humans Idioma: En Revista: Cancer Res Commun Ano de publicação: 2024 Tipo de documento: Article